Fig. 3.
Combination of dasatinib, erlotinib and gemcitabine effectively inhibits tumor growth in vivo. Mice with subcutaneously established tumors from (A) BxPC3 (n=5) (B) or PANC1 (n=5) cells were treated with dasatinib (DTB) at 25 mg/kg daily and/or gemcitabine (GEM) at 20 mg/kg for every 3 days and/or erlotinib (ERL) at 50 mg/kg/daily or vehicle for 14 days. Growth curves for tumors are presented as the mean ± SD of five tumors in each data point.